Join
Live feed
·
PRReleasevia Quantisnow
Teva Pharmaceutical Industries Limited logo

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

ByQuantisnow·Wall Street's wire, on your screen.
TEVA· Teva Pharmaceutical Industries Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TEVA (Teva Pharmaceutical Industries Limited) and more on Quantisnow.